Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor
patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of …

Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development
with Boehringer Ingelheim for the once-daily, oral treatment of cancer. Afatinib …

Purpose New molecular targeted agents are needed for patients with non–small-cell lung
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …

Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …

Afatinib is an oral, irreversible ErbB family blocker that covalently binds to the kinase
domains of epidermal growth factor receptor (EGFR), human EGFRs (HER) 2, and HER4 …

Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major
forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers …

T790M mutation is the most common mechanism of acquired resistance to first-generation
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). To overcome this …

The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small
cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC …

Small molecular tyrosine kinase inhibitors (smTKIs) are in the centre of the very quickly
expanding area of personalized chemotherapy and oral applicability thereof. The number of …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers
in non-small-cell lung cancer (NSCLC). Significant developments have taken place which …